Literature DB >> 25859838

Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

Bilal Farooqi1, Josh Simmons, Zhonglin Hao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25859838     DOI： 10.1007/s12029-015-9711-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  20 in total

1.  Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.

Authors:  Kazue Shiozawa; Manabu Watanabe; Hiroki Takenaka; Hidenari Nagai; Koji Ishii; Ken Sakai; Yasukiyo Sumino
Journal:  Hepatogastroenterology       Date:  2010 Jul-Aug

2.  Managing tumor lysis syndrome in 2010.

Authors:  Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2010-02

3.  Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.

Authors:  Ganapathy Krishnan; Karl D'Silva; Anas Al-Janadi
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

4.  Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.

Authors:  Z Nikolic-Tomasevic; S Jelic; I Popov; D Radosavljevic
Journal:  J Chemother       Date:  2000-06       Impact factor: 1.714

Review 5.  Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.

Authors:  Danielle Ferraro; John Zalcberg
Journal:  Ther Adv Med Oncol       Date:  2014-09       Impact factor: 8.168

Review 6.  Tumour lysis syndrome in solid tumours.

Authors:  C Gemici
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-12       Impact factor: 4.126

7.  Niacin hepatitis.

Authors:  D J Patterson; E W Dew; F Gyorkey; D Y Graham
Journal:  South Med J       Date:  1983-02       Impact factor: 0.954

8.  Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.

Authors:  Wu-Shiung Huang; Chang-Hsu Yang
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan.

Authors:  Ilhan Oztop; Binnaz Demirkan; Arzu Yaren; Oktay Tarhan; Bulent Sengul; Cagnur Ulukus; Davut Akin; Mehmet Sen; Ugur Yilmaz; Mehmet Alakavuklar
Journal:  Tumori       Date:  2004 Sep-Oct
View more
  3 in total

1.  Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.

Authors:  Helena S Gouveia; Sílvia O Lopes; Ana Luísa Faria
Journal:  BMJ Case Rep       Date:  2018-03-15

Review 2.  A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer.

Authors:  Zaid Ansari; Dawood Findakly; Jue Wang
Journal:  Cureus       Date:  2020-05-24

3.  Acute gouty arthritis following percutaneous cryoablation of renal cell carcinoma.

Authors:  Ahmed-Zayn Mohamed; William J Wallach; Sen Lu; Bruce Zwiebel; Glenn Hoots
Journal:  Radiol Case Rep       Date:  2019-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.